New Abbott Kaletra® (lopinavir ritonavir) Lower-Strength Scratch pad for Pediatric Exercise Approved in Europe
Patient Public: Health Professional: Forum Threads: 0 Abbott announced that it has received marketing authorization from the European Commission representing the new, lower-strength tablet formulation of the company's leading HIV protease inhibitor, Kaletra® (lopinavir ritonavir). The Kaletra memo pad can be taken with or without food and does not require refrigeration.
European Commission approval is significant for distinct developing countries because they crave documentation of the marketing authorization to access a Certificate of Pharmaceutical Product (CPP) recurrently a prerequisite for regulatory filing in developing countries.
In order to expedite review in developing countries, Abbott is working with regulatory agencies on a country-by-country basis to negotiate submissions before the CPP is available. Abbott intends to make the lower-strength writing- available or approved in 155 countries around the world, just as it has done with the man tablet.
The lower-strength Kaletra formulation is the first and only co-formulated protease inhibitor tablet that can be used in children of appropriate age, weight or body skin area, representing a meaningful breakthrough for clinicians treating children with HIV in both developed and developing countries," said Carlo Giaquinto, M.D.,
Department of Pediatrics, University of Padua, Italy, stool of PENTA (Pediatric European Network championing Treatment of AIDS). The lower-strength Kaletra tablet offers HIV-positive children recent benefits not available with the current soft capsules or spoken solution, enhancing the dosing convenience without compromising efficacy.
Simple scribbling form the lower-strength spiral-bound notebook is bounteous convenient to administer than the oral solution.
Dosing is with or without food, if only patients more advantageous flexibility the current soft capsule formulation should be taken with food. No required refrigeration to the current soft capsule formulation or said solution, which require refrigeration, the new Kaletra note- can be stored at room temperature.
HIV Back continues to annex a devastating effect on millions of children around the world, especially those patients living in resource-limited settings," said Scott Brun, M.D., Global Pharmaceutical Research and Development, Abbott.
The new lower-strength Kaletra formulation is another case history of Abbott's continued commitment to advancing treatment and care for the HIV community." Kaletra Lower-Strength Tablet Availability Based on the U.S.
Cookery and Drug Administration (FDA) approval on Nov. 9, 2007, Abbott is shipping the lower-strength tablets to countries that admit issued approved relinquishment orders.
Other African rule are now also talking to Abbott approximately the possibility of waiver shipments. The World Health Crowd guide lopinavir ritonavir as the preferred treatment for children who no longer respond to first-line HIV medicine. The U.S.
Department of Health and Hominoid Service recommends lopinavir ritonavir for the initial treatment of children with HIV. Kaletra Lower-Strength Note- The virgin tablet formulation will complement Kaletra oral solution, which has been available for pediatric manipulate thanks to its U.S.
September 2000. For paediatric patients, lower-strength Kaletra tablets will offer deeper dosing flexibility. The price of the lower-strength tablet will be half the price of the original-strength tablet in all places it is available.
Abbott's Commitment to Fighting HIV AIDS HIV AIDS is a extensive botheration that requires shared commitment and shared responsibility.